LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.

What symbol and exchange does Leonabio shares trade?

Leonabio trades on the NASDAQ stock market under the symbol LONA.

What is Leonabio stock price doing today?

As of November 11, 2026, LONA stock price declined to $3.88 with 32,956 million shares trading.

What is Leonabio's Beta?

LONA has a beta of 0.16, meaning it tends to be less sensitive to market movements. LONA has a correlation of 0.00 to the broad based SPY ETF.

How much is Leonabio worth?

LONA has a market cap of $36.56 million. This is considered a Sub-Micro Cap stock.

What are the top ETFs holding Leonabio?

The top ETF exchange traded funds that LONA belongs to (by Net Assets): VTI, VXF, IWC, DFMC, DCOR.

What are the support and resistance levels for Leonabio (LONA)?

LONA support price is $3.67 and resistance is $4.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LONA shares will trade within this expected range on the day.